Last Updated: December 12, 2016
Filed under:
Print Friendly, PDF & Email

By Michael J. Alkire, COO of Premier Members of the Premier alliance commend the solicitor general for recommending the Supreme Court hear the case of Sandoz v. Amgen. This landmark case could overturn a lower court decision requiring biosimilar manufacturers (more…)

Last Updated: October 28, 2016
Filed under:
Print Friendly, PDF & Email

HealthcareDive: Over the past couple of years, Dr. Bimal Shah has seen dozens of value-based drug pricing contract negotiations falter. As vice president for the research division of Premier, a provider-owned healthcare improvement company, he oversees research to identify opportunities for (more…)

Last Updated: October 21, 2016
Filed under:
Print Friendly, PDF & Email

PharmExec: Bimal Shah: Real-world evidence (RWE) is the intersection between the structured rigor of the randomized clinical trial (RCT), and the clinical exposure a treatment receives once it enters medical practice. As explored in the following Roundtable discussion, drug manufacturers, (more…)

Last Updated: August 2, 2016
Print Friendly, PDF & Email

  • August 23, 2016
    11:00 am - 12:00 pm

Heart failure is a complex, progressive disease that carries a significant risk of hospitalization and death. In addition, heart failure has a substantial and increasing impact on patients and the healthcare system. Join this live webinar at 11 a.m. EDT on Tuesday, August 23, for an introduction to Entresto, a novel new agent used to (more…)

Last Updated: August 2, 2016
Print Friendly, PDF & Email

  • August 23, 2016
    2:00 pm - 3:00 pm

Heart failure is a complex, progressive disease that carries a significant risk of hospitalization and death. In addition, heart failure has a substantial and increasing impact on patients and the healthcare system. Join this live webinar at 2 p.m. EDT on Tuesday, August 23, for an introduction to Entresto, a novel new agent used to (more…)

Last Updated: August 25, 2016
Filed under:
Print Friendly, PDF & Email

HFMA: Drug shortages contribute to rising healthcare costs. A 2014 analysis by Premier found that purchasing costlier generic substitutes for drugs in short supply drove up costs an average of $229.7 million annually. In fact, the figure is likely much higher (more…)